Gilead Sciences Inc. (GILD)
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company's oncology pipeline.
Gilead to acquire Tubulis GmbH for up to $5 billion
Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, boosting the U.S. drugmaker's pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Markets Haven't Changed. These 2 Cheap Dividends Still Rule
Fear is up, markets are down—and we contrarians know that times like these are when we go shopping for cheap dividends.
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Gilead Sciences (GILD) closed at $139.37, marking a +2.22% move from the previous day.
Gilead Sciences, Inc. (GILD) M&A Call Transcript
Gilead Sciences, Inc. (GILD) M&A Call Transcript
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today
Gilead Sciences (GILD) closed the most recent trading day at $134.25, moving 1.92% from the previous trading session.
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.
Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal
GILD expands into autoimmune therapies with an acquisition deal with Ouro Medicines, adding OM336 and advancing its push into next-gen immunology platforms.
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotech company developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T cell engager, to Gilead's inflammation portfolio.
